查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1714237

細胞激素市場－全球產業規模、佔有率、趨勢、機會和預測，按細胞激素類型、治療應用、地區和競爭細分，2020-2030 年

Cytokine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Cytokine Type, By Therapeutics Application, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 184 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球細胞激素市場價值為 952.3 億美元，預計將大幅擴張，到 2030 年達到新的高度，預計複合年成長率為 7.82%。細胞激素——參與免疫系統調節、發炎和細胞間通訊的關鍵訊號蛋白——已成為治療創新和疾病管理的關鍵。

市場概覽
預測期 2026-2030
2024年市場規模 952.3億美元
2030年市場規模 1499.5億美元
2025-2030 年複合年成長率 7.82%
成長最快的領域 癌症
最大的市場 北美洲

細胞激素生物學的持續進步正在開啟癌症、自體免疫和傳染病領域的新臨床應用。全球慢性病盛行率的激增推動了基於細胞因子的療法的開發和應用，為市場持續成長奠定了基礎。

在不斷成長的研發投資和精準醫療計畫的支持下，治療創新正在將細胞激素療法轉變為現代治療方案的組成部分。對生物製劑和個人化醫療保健解決方案的日益依賴進一步推動了生物製藥和生物技術行業的產品開發。隨著臨床應用的擴大和產業關注度的提高，細胞激素市場將在未來幾年迎來動態發展。

關鍵市場促進因素

研發（R&D）的策略重要性

2023年，美國生技製藥公司在研發方面投資近960億美元，凸顯了該產業對創新的承諾。這種關注導致了：

開發具有更高安全性和有效性的突破性細胞激素療法

增強提供差異化解決方案的公司的競爭地位

投資者和策略夥伴的興趣日益濃厚

更廣泛的臨床用途，進而擴大市場潛力

主要市場挑戰

安全性和不良反應

主要安全相關問題包括：

長期臨床試驗以確定安全劑量和治療參數

可能影響治療採用和患者信任的不良反應風險

加強監管，可能會延遲核准並增加合規負擔

為了解決這些問題，公司正在投資：

臨床前模型與高階體外研究

臨床試驗期間的全面安全監控

繼續研究分子機制以增強靶向性並最大限度地減少副作用

主要市場趨勢

個人化細胞激素療法的出現

細胞激素治療領域正在經歷向個人化醫療的顯著轉變。透過利用生物標記和基因分析，個人化細胞激素治療可提供：

透過有針對性的介入改善治療效果

透過針對患者的給藥策略減少不良反應

提高生物製劑在主流治療方案的接受度

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球細胞激素市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依細胞激素類型（腫瘤壞死因子-TNF、白血球介素-Il、干擾素-IFN、表皮生長因子-EGF、其他）
    • 依治療應用（癌症、氣喘及呼吸道發炎、關節炎、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美細胞激素市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲細胞激素市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第8章：亞太細胞激素市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：南美細胞激素市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東與非洲細胞激素市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 13 章：全球細胞激素市場：SWOT 分析

第 14 章：競爭格局

  • GlaxoSmithkline PLC
  • Novartis AG
  • Amgen Inc
  • Pfizer Inc.
  • Sanofi SA
  • AstraZeneca plc
  • Biocon Limited
  • Abbvie Inc
  • Johnson and Johnson
  • UCB SA

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 16140

The Global Cytokine Market was valued at USD 95.23 billion in 2024 and is expected to witness significant expansion, reaching new heights by 2030 with a projected CAGR of 7.82%. Cytokines-key signaling proteins involved in immune system regulation, inflammation, and intercellular communication-have become pivotal in both therapeutic innovation and disease management.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 95.23 Billion
Market Size 2030USD 149.95 Billion
CAGR 2025-20307.82%
Fastest Growing SegmentCancer
Largest MarketNorth America

Ongoing advancements in cytokine biology are unlocking novel clinical applications across cancer, autoimmune, and infectious diseases. The surge in chronic illness prevalence globally has driven the development and uptake of cytokine-based therapies, positioning the market for sustained growth.

Therapeutic innovations, supported by growing R&D investments and precision medicine initiatives, are transforming cytokine therapies into integral components of modern treatment protocols. Increasing reliance on biologics and personalized healthcare solutions is further fueling product development across biopharmaceutical and biotechnology industries. With expanding clinical use and heightened industry focus, the cytokine market is poised for dynamic evolution in the years ahead.

Key Market Drivers

Strategic Importance of Research and Development (R&D)

R&D remains a fundamental catalyst for growth in the cytokine market. As the biological complexity of cytokines becomes better understood, new opportunities for drug development and therapeutic application continue to emerge.

In 2023, U.S. biopharmaceutical firms invested nearly USD 96 billion in R&D, underlining the industry's commitment to innovation. This focus has led to:

Development of breakthrough cytokine therapies with improved safety and efficacy profiles

Strengthened competitive positioning for companies offering differentiated solutions

Heightened interest from investors and strategic collaborators

Broader clinical use, thereby expanding the market potential

Robust R&D pipelines, along with strategic collaborations between research institutions and industry stakeholders, are expected to further accelerate the development of targeted cytokine therapies.

Key Market Challenges

Safety and Adverse Effects

The therapeutic use of cytokines presents inherent challenges due to their potent biological activity. While effective, cytokines can produce complex and, at times, unpredictable physiological responses.

Major safety-related issues include:

Prolonged clinical trials to establish safe dosing and treatment parameters

Risk of adverse effects that may affect treatment adoption and patient trust

Heightened regulatory oversight, which may delay approvals and increase compliance burdens

To address these concerns, companies are investing in:

Preclinical models and advanced in vitro studies

Comprehensive safety monitoring during clinical trials

Continued research into molecular mechanisms to enhance targeting and minimize side effects

Key Market Trends

Emergence of Personalized Cytokine Therapies

The cytokine therapy landscape is witnessing a notable shift toward personalized medicine. By leveraging biomarkers and genetic profiling, personalized cytokine treatments offer:

Improved therapeutic outcomes through targeted intervention

Reduced adverse effects via patient-specific dosing strategies

Enhanced acceptance of biologics in mainstream treatment regimens

Pharmaceutical developers are increasingly investing in companion diagnostics, biomarker discovery, and niche formulations to align with this trend. These developments are reshaping therapeutic strategies and enabling a patient-centric approach, which is expected to be a significant market differentiator moving forward.

Key Market Players

  • GlaxoSmithKline PLC
  • Novartis AG
  • Amgen Inc
  • Pfizer Inc.
  • Sanofi SA
  • AstraZeneca plc
  • Biocon Limited
  • Abbvie Inc
  • Johnson and Johnson
  • UCB S.A

Report Scope:

In this report, the Global Cytokine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cytokine Market, By Cytokine Type:

  • Tumour Necrosis Factor-TNF
  • Interleukins-Il
  • Interferons-IFN
  • Epidermal Growth Factor-EGF
  • Other

Cytokine Market, By Therapeutics Application:

  • Cancer
  • Asthma and Airway Inflammation
  • Arthritis
  • Other

Cytokine Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cytokine Market.

Available Customizations:

Global Cytokine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cytokine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Cytokine Type (Tumour Necrosis Factor-TNF, Interleukins-Il, Interferons-IFN, Epidermal Growth Factor-EGF, Other)
    • 5.2.2. By Therapeutics Application (Cancer, Asthma and Airway Inflammation, Arthritis, Other)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Cytokine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Cytokine Type
    • 6.2.2. By Therapeutics Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cytokine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Cytokine Type
        • 6.3.1.2.2. By Therapeutics Application
    • 6.3.2. Canada Cytokine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Cytokine Type
        • 6.3.2.2.2. By Therapeutics Application
    • 6.3.3. Mexico Cytokine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Cytokine Type
        • 6.3.3.2.2. By Therapeutics Application

7. Europe Cytokine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Cytokine Type
    • 7.2.2. By Therapeutics Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cytokine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Cytokine Type
        • 7.3.1.2.2. By Therapeutics Application
    • 7.3.2. United Kingdom Cytokine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Cytokine Type
        • 7.3.2.2.2. By Therapeutics Application
    • 7.3.3. Italy Cytokine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Cytokine Type
        • 7.3.3.2.2. By Therapeutics Application
    • 7.3.4. France Cytokine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Cytokine Type
        • 7.3.4.2.2. By Therapeutics Application
    • 7.3.5. Spain Cytokine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Cytokine Type
        • 7.3.5.2.2. By Therapeutics Application

8. Asia-Pacific Cytokine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Cytokine Type
    • 8.2.2. By Therapeutics Application
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Cytokine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Cytokine Type
        • 8.3.1.2.2. By Therapeutics Application
    • 8.3.2. India Cytokine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Cytokine Type
        • 8.3.2.2.2. By Therapeutics Application
    • 8.3.3. Japan Cytokine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Cytokine Type
        • 8.3.3.2.2. By Therapeutics Application
    • 8.3.4. South Korea Cytokine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Cytokine Type
        • 8.3.4.2.2. By Therapeutics Application
    • 8.3.5. Australia Cytokine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Cytokine Type
        • 8.3.5.2.2. By Therapeutics Application

9. South America Cytokine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Cytokine Type
    • 9.2.2. By Therapeutics Application
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Cytokine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Cytokine Type
        • 9.3.1.2.2. By Therapeutics Application
    • 9.3.2. Argentina Cytokine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Cytokine Type
        • 9.3.2.2.2. By Therapeutics Application
    • 9.3.3. Colombia Cytokine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Cytokine Type
        • 9.3.3.2.2. By Therapeutics Application

10. Middle East and Africa Cytokine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Cytokine Type
    • 10.2.2. By Therapeutics Application
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Cytokine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Cytokine Type
        • 10.3.1.2.2. By Therapeutics Application
    • 10.3.2. Saudi Arabia Cytokine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Cytokine Type
        • 10.3.2.2.2. By Therapeutics Application
    • 10.3.3. UAE Cytokine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Cytokine Type
        • 10.3.3.2.2. By Therapeutics Application

11. Market Dynamics

  • 11.1. Driver
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Cytokine Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. GlaxoSmithkline PLC
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Novartis AG
  • 14.3. Amgen Inc
  • 14.4. Pfizer Inc.
  • 14.5. Sanofi SA
  • 14.6. AstraZeneca plc
  • 14.7. Biocon Limited
  • 14.8. Abbvie Inc
  • 14.9. Johnson and Johnson
  • 14.10. UCB S.A

15. Strategic Recommendations

16. About Us & Disclaimer